This combination is indicated for reducing intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension when a single medication does not provide adequate pressure control.

Brinzolamide is a strong inhibitor of carbonic anhydrase II (CA-II), the predominant isoenzyme in the eye. By inhibiting CA-II in the ciliary processes, it reduces aqueous humor production through decreased bicarbonate ion formation and reduced sodium and fluid transport.

Timolol is a non-selective beta-adrenergic receptor blocker without significant intrinsic sympathomimetic, myocardial depressant, or membrane-stabilizing effects. It lowers intraocular pressure primarily by reducing aqueous humor production and slightly increasing outflow. Together, these two agents act via different mechanisms to provide an additive reduction in intraocular pressure compared to either drug alone.

The recommended dosage is one drop in the conjunctival sac of the affected eye(s) twice daily.

Potential interactions may occur with antifungal agents (such as ketoconazole, itraconazole), antivirals (ritonavir), macrolide antibiotics, calcium channel blockers, beta-blockers, antiarrhythmic drugs, digitalis glycosides, parasympathomimetics, quinidine, and cimetidine.

This medication should not be used in patients with known hypersensitivity to Brinzolamide, other sulphonamides, Timolol, or any component of the formulation.

Common side effects include blurred vision, eye pain, eye irritation, and a foreign body sensation in the eyes.

This combination is classified as Pregnancy Category C. There are limited data on its use in pregnant women, and animal studies have shown potential risks. It should be used during pregnancy only if the expected benefit outweighs the possible risk to the fetus. Timolol has been detected in breast milk, while Brinzolamide excretion in human milk is uncertain (though observed in animal studies). However, at therapeutic doses, no harmful effects on breastfed infants are expected. This combination may be used during breastfeeding if clinically necessary.

Acid-base imbalance has been reported with oral carbonic anhydrase inhibitors. If signs of serious hypersensitivity or adverse reactions occur, the medication should be discontinued. Due to the presence of Timolol, cardiovascular and respiratory adverse effects similar to systemic beta-blockers may occur. Cardiac failure should be well controlled before starting therapy, and patients with severe heart disease should be closely monitored, including pulse rate checks.

Drugs for miotics and glaucoma

Store below 30°C, protected from light and moisture. Avoid touching the dropper tip to any surface, including the eyes or fingers, to prevent contamination. Keep the bottle tightly closed when not in use. Do not use beyond 4 weeks after first opening.